The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community
The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community
复制标题
DOI：
10.1016/j.ejca.2013.10.011
复制
发表时间：
2014-01-01
影响因子：
8.4
通讯作者：
Seymour, Lesley
中科院分区：
文献类型：
--
作者：
Liu, Yan;Litiere, Saskia;Seymour, Lesley
目的：随着新型靶向药物的使用增加和高成像技术的发展，主要针对细胞毒性药物和解剖成像开发的实体瘤疗效评估标准 (RECIST) 1.1 已显示出局限性。对 RECIST 用户进行了一项调查，以确定他们对未来 RECIST 标准的关注点和建议。方法：要求 RECIST 合作的 140 名主要合作伙伴填写一份调查问卷。 49 个问题涉及 (a) 对 RECIST 1.1 的满意度和担忧； (b) 使用修改后的 RECIST 标准和 (c) 对下一个 RECIST 版本的建议。结果：收到 65 份回复。 52.3% 的受访者对 RECIST 1.1 表示满意，而 10.8% 的受访者表示不满意。潜在的弱点包括：(a) 缺乏潜在的早期反应指标，例如功能成像，(b) 缺乏对罕见肿瘤类型的验证，(c) 缺乏对新型（靶向）药物的验证。建议很多，其中最多的是两点：制定某些疾病类型的子标准以及包括用于评估的先进成像技术。结论：收到了优化下一版本的建设性建议。持续的数据收集将有可能研究氟脱氧葡萄糖-正电子发射断层扫描（FDG-PET）成像在肿瘤评估中的可能用途，验证RECIST是否/仍然适用于新型靶向治疗，并考虑特定疾病类型标准的需要。 (C) 2013 Elsevier Ltd. 保留所有权利。
Purpose: With the increasing use of novel targeted agents and the development of high imaging techniques, response evaluation criteria in solid tumour (RECIST) 1.1 developed primarily for cytotoxic agents and anatomic imaging, has demonstrated limitations. A survey was conducted of RECIST users to identify concerns and their suggestions for future RECIST criteria.Methods: 140 key partners of the RECIST collaboration were asked to complete a questionnaire. The 49 questions concerned (a) satisfaction and concerns with RECIST 1.1; (b) use of modified RECIST criteria and (c) suggestions for the next RECIST Version.Results: Sixty-five replies were received. 52.3% responders were satisfied with RECIST 1.1, while 10.8% indicated dissatisfaction. Areas of potential weakness included: (a) lack of incorporation of potential early indicators of response such as functional imaging, (b) lack of validation in rarer tumour types and (c) lack of validation for novel (targeted) agents. Suggestions were multiple, with highest numbers on two points: developing sub-criteria for certain disease types and including advanced imaging techniques for the evaluation.Conclusions: Constructive suggestions were received for optimising the next version. Ongoing data collection will make it possible to investigate the possible utilisation of fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging in tumour assessment, to verify whether RECIST is/can still be applicable in novel targeted therapy and to consider the need for criteria for specific disease types. (C) 2013 Elsevier Ltd. All rights reserved.